canertinib has been researched along with Pancreatic Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Batra, SK; Ganti, AK; Haridas, D; Lakshmanan, I; Ponnusamy, MP; Rachagani, S; Seshacharyulu, P; Yan, Y | 1 |
1 other study(ies) available for canertinib and Pancreatic Neoplasms
Article | Year |
---|---|
Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer.
Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Morpholines; Mucin-4; Pancreatic Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |